EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Validation of GenProb ‐ T1D and its clinical utility for differentiating types of diabetes in a biobank from a US healthcare system

Liana K Billings, Zhuqing Shi, Ashley J Mulford, Jun Wei, Huy Tran, Annabelle Ashworth, S Lilly Zheng, Henry M Dunnenberger, Peter J Hulick, Alan R Sanders, Jianfeng Xu iD

Journal of Diabetes Investigation · 2025

DOI: 10.1111/jdi.14297 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Diabetes Investigation, 2025. Verfasst von Liana K Billings und 10 weiteren Autor:innen. Beteiligte Einrichtung: Endeavor Health, Evanston, IL, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Biological Specimen Banks. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atypical diabetes with overlapping clinical features of type 1 (T1D) and type 2 (T2D) is common and challenging diagnostically and for implementing effective treatment. Here, we validate a recently reported genetic probability of type 1 diabetes (GenProb‐T1D) from the UK Biobank (UKB) for differentiating type 1 diabetes and type 2 diabetes in a diabetes patient cohort from a healthcare system‐based biobank in the USA. Among 3,363 diabetes patients, we confirmed the performance of GenProb‐T1D in differentiating typical type 1 diabetes vs type 2 diabetes. Furthermore, for 359 atypical diabetes patients, those with GenProb‐T1D higher than the pre‐defined cutoff derived from the UKB had clinical presentations more consistent with that of typical type 1 diabetes. Similar findings were found in participants of European and non‐European ancestries. This study provides necessary validation to translate GenProb‐T1D into genetic testing in a multi‐ancestry cohort. Measuring underlying genetic susceptibility of type 1 diabetes and type 2 diabetes can supplement current clinical tools for earlier and more accurate diagnoses of diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Biological Specimen BanksHumansMaleFemaleUnited StatesMiddle AgedAdultGenetic Predisposition to DiseaseDiagnosis, DifferentialAgedCohort StudiesGenetic Testing

Stichwörter der Autor:innen

diabetes mellitispolygenic

Autor:innen und Institutionen

  • Endeavor Health, Evanston, IL, USA.
  • University of Chicago Pritzker School of Medicine, Chicago, IL, USA.

ORCID-Profile: Jianfeng Xu

Zitieren

APA

Billings, L. K., Shi, Z., Mulford, A. J., Wei, J., Tran, H., Ashworth, A., Zheng, S. L., Dunnenberger, H. M., Hulick, P. J., Sanders, A. R., & Xu, J. (2025). Validation of GenProb ‐ T1D and its clinical utility for differentiating types of diabetes in a biobank from a US healthcare system. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14297

Vancouver

Billings LK, Shi Z, Mulford AJ, Wei J, Tran H, Ashworth A, et al. Validation of GenProb ‐ T1D and its clinical utility for differentiating types of diabetes in a biobank from a US healthcare system. Journal of Diabetes Investigation. 2025. doi:10.1111/jdi.14297

BibTeX
@article{Billings2025,
  author = {Billings, Liana K and Shi, Zhuqing and Mulford, Ashley J and Wei, Jun and Tran, Huy and Ashworth, Annabelle and Zheng, S Lilly and Dunnenberger, Henry M and Hulick, Peter J and Sanders, Alan R and Xu, Jianfeng},
  title = {Validation of GenProb ‐ T1D and its clinical utility for differentiating types of diabetes in a biobank from a US healthcare system},
  journal = {Journal of Diabetes Investigation},
  year = {2025},
  doi = {10.1111/jdi.14297}
}
Kostenlos starten →